KATHRYN SHELTON: Open Payments
NPI 1164996641 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,022 in 163 payments from 11 companies in 2025. Trend: 2023 $1,891 · 2024 $1,839 · 2025 $2,022
Food & beverage: $2,022
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 28 | $440 |
| Teva Pharmaceuticals USA, Inc. | 21 | $335 |
| Neurocrine BioSciences, Inc. | 26 | $296 |
| Lundbeck LLC | 13 | $244 |
| ABBVIE INC. | 31 | $153 |
| Otsuka America Pharmaceutical, Inc. | 17 | $149 |
| Vanda Pharmaceuticals Inc. | 11 | $140 |
| E.R. Squibb & Sons, L.L.C. | 9 | $135 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $41 |
Products named: ARISTADA, INGREZZA, ABILIFY ASIMTUFII, UZEDY, VRAYLAR, AUSTEDO XR, FANAPT, COBENFY.
Industry payments across OK — which companies pay providers there.
